123696-01-5

Basic information

• Product Name: 5-METHOXYPYRIDAZIN-3(2H)-ONE
• Synonyms: 5-METHOXYPYRIDAZIN-3(2H)-ONE;AURORA KA-3645;5-Methoxy-2,3-dihydropyridazin-3-one;3-hydroxy-5-Methoxypyridazine;-METHOXYPYRIDAZIN-3(2H)-ONE;3-methoxy-3(2H)-pyridazinone;3(2H)-Pyridazinone,5-methoxy-
• CAS NO: 123696-01-5
• Molecular Formula: C5H6N2O2
• Molecular Weight: 126.11
• EINECS: 200-001-2
• Mol File: 123696-01-5.mol

Chemical Properties

• Melting Point: 148-150 °C
• Boiling Point: 363 °C at 760 mmHg
• Flash Point: 173.3 °C
• Appearance: /
• Density: 1.3 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 10.57±0.40(Predicted)
• CAS DataBase Reference: 5-METHOXYPYRIDAZIN-3(2H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHOXYPYRIDAZIN-3(2H)-ONE(123696-01-5)
• EPA Substance Registry System: 5-METHOXYPYRIDAZIN-3(2H)-ONE(123696-01-5)

Safety Data

• Hazardous Substances Data: 123696-01-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Methoxypyridazin-3(2H)-one is used as a building block for the synthesis of various pharmaceuticals due to its potent biological activities. Its antimicrobial and antifungal properties make it a valuable component in the development of new drugs to combat resistant infections.
Used in Agrochemical Industry:
In the agrochemical industry, 5-Methoxypyridazin-3(2H)-one is used as a building block for the synthesis of agrochemicals, leveraging its antimicrobial and antifungal properties to protect crops from diseases and pests.
Used in Organic Synthesis:
5-Methoxypyridazin-3(2H)-one is used as a reagent in organic synthesis, particularly for the preparation of heterocyclic compounds. Its unique structure and reactivity make it an essential tool for creating complex organic molecules.
Used in Chemical Research:
As a valuable tool in chemical research, 5-Methoxypyridazin-3(2H)-one aids in the exploration of new chemical reactions and the development of innovative synthetic pathways, contributing to advancements in the field of chemistry.

Upstream product

• 152732-22-4 4-bromo-5-methoxypyridazin-3(2H)-one 
• 938045-16-0 2-((benzyloxy)methyl)-4-chloro-5-methoxypyridazin-3(2H)-one 
• 173206-12-7 4-chloro-5-methoxy-2-(tetrahydro-2H-pyran-2-yl)-3(2H)-pyridazinone 
• 173206-14-9 5-methoxy-2-(tetrahydro-2H-pyran-2-yl)-3(2H)-pyridazinone 
• 63910-43-0 4-chloro-5-methoxypyridazin-3-(2H)-one 

Downstream Products

• 2096-20-0 3,5-dimethoxypyridazine 
• 20733-11-3 4-methoxypyridazine 
• 123696-02-6 3-chloro-5-methoxy-pyridazine 
• 17285-29-9 5-hydroxy-3(2H)-pyridazinone 

Relevant articles and documents

A large scale synthesis of 3-chloro-5-methoxypyridazine

A large scale synthesis of 3-chloro-5-methoxypyridazine was developed (18 moles) that relies on the protection of the pyridazinone nitrogen of 4,5-dichloro-3(2H)-pyridazinone as the tetrahydropyranyl derivative 2. The 5-chloro position of the protected pyridazinone was selectively displaced with methoxide to give 3 followed by catalytic hydrogenation of the 4-chloro group to give 4. Removal of the protecting group with acid followed by phosphorous oxychloride treatment gave the target compound 6 in good yield. This route is superior to the previously described synthesis of this compound.

Pyridazines with Heteroatom Substituents in Position 3 and 5, Part 1: 5-Hydroxy-3(2H)-pyridazinone and Its Derivatives

The synthesis of the title compound 7 was achieved starting with mucochloric acid via the pyridazinones 1,2 and 6.The electrolytic ionisation constants for 7 were found to be 4.81 (+/-0.03) and -0.3 (+/-0.3).Crystal structure analyses were performed for 7 and its "fixed" derivatives 6 and 9. - Keywords.Synthesis of 5-methoxy- and 5-hydroxy-3(2H)-pyridazinones; pKa Values of 5-hydroxy-3(2H)-pyridazinone; Crystal structure of 3(2H)-pyridazinones.

HETEROARYLBENZIMIDAZOLE COMPOUNDS

The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF

A compound represented by Formula [1] (in the formula, Z1 represents N, CH, or the like; X1 represents NH or the like; R1 represents a heteroaryl group or the like; each of R2, R3, and R4 represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R5 represents a heteroaryl group or the like) or salt thereof.

N-phenyl-4-pyrazolo[1,5-6]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy

Glycogen synthase kinase 3 regulates glycogen synthase, the rate-determining enzyme for glycogen synthesis. Liver and muscle glycogen synthesis is defective in type 2 diabetics, resulting in elevated plasma glucose levels. Inhibition of GSK-3 could potentially be an effective method to control plasma glucose levels in type 2 diabetics. Structure-activity studies on a N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine series have led to the identification of potent and selective compounds with good cellular efficacy. Molecular modeling studies have given insights into the mode of binding of these inhibitors. Since the initial leads were also potent inhibitors of CDK-2/CDK-4, an extensive SAR was performed at various positions of the pyrazolo[1,5-b] pyridazin core to afford potent GSK-3 inhibitors that were highly selective over CDK-2. In addition, these inhibitors also exhibited very good cell efficacy and functional response. A representative example was shown to have good oral exposure levels, extending their utility in an in vivo setting. These inhibitors provide a viable lead series in the discovery of new therapies for the treatment of type 2 diabetes.